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Abstract
The enormous genetic variability reported in HIV-1 has posed problems in the treatment of infected individuals.
This is evident in the form of HIV-1 resistant to antiviral agents, neutralizing antibodies and cytotoxic T
lymphocytes (CTLs) involving multiple viral gene products. Based on this, it has been suggested that a
comprehensive analysis of the polymorphisms in HIV proteins is of value for understanding the virus transmission
and pathogenesis as well as for the efforts towards developing anti-viral therapeutics and vaccines. This study, for
the first time, describes an in-depth analysis of genetic variation in Vpr using information from global HIV-1 isolates
involving a total of 976 Vpr sequences. The polymorphisms at the individual amino acid level were analyzed. The
residues 9, 33, 39, and 47 showed a single variant amino acid compared to other residues. There are several amino
acids which are highly polymorphic. The residues that show ten or more variant amino acids are 15, 16, 28, 36,
37, 48, 55, 58, 59, 77, 84, 86, 89, and 93. Further, the variant amino acids noted at residues 60, 61, 34, 71 and 72
are identical. Interestingly, the frequency of the variant amino acids was found to be low for most residues. Vpr
is known to contain multiple CTL epitopes like protease, reverse transcriptase, Env, and Gag proteins of HIV-1.
Based on this, we have also extended our analysis of the amino acid polymorphisms to the experimentally defined
and predicted CTL epitopes. The results suggest that amino acid polymorphisms may contribute to the immune
escape of the virus. The available data on naturally occurring polymorphisms will be useful to assess their potential
effect on the structural and functional constraints of Vpr and also on the fitness of HIV-1 for replication.
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Introduction
Humoral and cellular responses have been implicated in
controlling viral and bacterial infections in addition to the
host's innate immune responses. This is, indeed, demon-
strated in the context of HIV-1 infection [1-3]. Specifically,
CTL responses against the virus have been shown to limit
the virus replication at a low level in the infected individ-
uals. This is evident in the inverse correlation of CTL
responses vs. virus load observed in acutely infected indi-
viduals [4-6]. Utilizing the rhesus macaque/SIV infection
model, a suppressive effect on virus replication was
shown for CTLs [7]. However, the initial CTL responses
are not able to contain the virus at a later stage, possibly
due to the emergence of viral variants that evade the
immune responses resulting in continued virus replica-
tion [8,9]. Hence, an understanding of the CTL escape var-
iants of HIV is important both in natural viral infections
and also in the context of vaccine-induced immunity for
developing effective CTL based polyvalent vaccines for
containing diverse HIV-1 strains [10]. This is an area of
research which is actively being pursued by several inves-
tigators [11,12].
The genome of HIV-1 has been shown to code for two reg-
ulatory proteins (Tat and Rev) and four auxiliary proteins
(Vif, Vpr, Vpu and Nef) in addition to the Gag, Pol, and
Env structural proteins [13]. The regulatory proteins Tat
and Rev are essential for virus replication. Rev is involved
in the transport of genomic and partially spliced subge-
nomic mRNA from the nucleus to the cytoplasm [14]. Tat
is known as an activator of transcription of viral and cel-
lular RNA. Vif plays an important role in HIV-1 replica-
tion in peripheral blood mononuclear cells (PBMC).
Specifically, Vif prevents hypermutation in the newly
made viral DNA through its interaction with APOBEC3G
[15,16]. Vpr is known for its incorporation into the virus
particles. The interaction of Vpr with the Gag enables its
incorporation into the virus particle. Vpr is a multifunc-
tional protein and is involved in the induction of apopto-
sis, cell cycle arrest, and transcriptional activation [17].
Vpu plays a role in the particle release and degradation of
CD4 [14,18,19]. The features of Nef include downregula-
tion of cell surface receptors, interference with signal
transduction pathways, enhancement of virion infectivity,
induction of apoptosis in bystander cells, and protection
of infected cells from apoptosis [20-24].
Based on the data reported so far, it is clear that HIV-1
employs multiple strategies to successfully replicate in the
infected individuals [14,25,26]. The enormous genetic
variation that is generated through errors of reverse tran-
scriptase enzyme may provide a pool of variants to evade
the host immune responses against the virus and also
result in the emergence of drug resistant viruses during
treatment. In addition, it is also likely that the immuno-
suppressive effects of HIV-1 encoded proteins may atten-
uate the host immune responses in favor of the virus.
Upon infection of target cells by the virus, viral proteins
are synthesized for carrying out the functions related to
the virus replication and also exert effect on specific host
cell functions. In addition, viral proteins are also targeted
to the proteosomal degradation pathway. This process
results in the generation of peptides, which are then trans-
located to the ER through TAP and are presented on the
cell surface in association with human leukocyte antigen
(HLA) class I molecules. The genetic variability present in
the coding sequences of the virus may result in viral pro-
teins with alterations in the CTL epitopes, which may lead
to defective processing, presentation or lack of recognition
of the epitope by the reactive CTLs. This is the likely mech-
anism of the CTL escape by HIV-1 and other viruses. The
presence of multiple CTL epitopes has been demonstrated
in HIV-1 proteins including Gag, Pol, Vif, Vpr, Tat, Rev,
Vpu, Env and Nef. Though the characterization of the
epitopes with respect to the viral proteins is achievable in
individual cases, such an analysis at a population level is
difficult to carry out for the following reasons: i) HIV-1
exhibits high genetic variation in different regions of the
genome. The extent of heterogeneity among circulating
HIV-1 strains is described to be in the range of 20% or
more in relatively conserved proteins and up to 35% for
Env protein [11]. In addition, there is also extensive diver-
sity among HIV-1 within a subtype, ii) There are multiple
subtypes of HIV-1, and iii) There are variables at the HLA
loci. On the other hand, this limitation can be overcome
to some extent by utilizing alternative approaches where
information about CTL epitopes and their variants can be
inferred from the sequences available for HIV-1 [27-29].
The HIV sequence database has information about the
viral isolates from different parts of the world. This infor-
mation can be used as a source to assess the extent of nat-
urally occurring polymorphisms and their potential
impact on CTL epitopes. We hypothesize that mutations
or alterations in the residues which are part of the CTL
epitope in the Vpr molecule are likely to affect the epitope
at multiple levels (processing and recognition of the
epitope). Recently, studies have addressed this issue using
full length or partial HIV-1 genome sequences [30]. This
has prompted us to carry out a comprehensive analysis of
the extent of variation at the amino acid level in the aux-
iliary gene product Vpr of HIV-1.
The underlying reasons for the selection of Vpr for a com-
prehensive analysis are the following: i) Vpr is a virion
associated protein, ii) Vpr plays a critical role for the rep-
lication of virus in macrophages, iii) Vpr is a transcrip-
tional activator of HIV-1 and heterologous cellular genes,
iv) Vpr arrests cells at G2/M, v) Vpr induces apoptosis in
diverse cell types, vi) Vpr exhibits immune suppressiveVirology Journal 2008, 5:99 http://www.virologyj.com/content/5/1/99
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effect, vii) Vpr is present in the body fluids as an extracel-
lular protein, viii) Vpr is highly immunogenic, ix) Vpr is a
small protein comprising only 96 amino acids and x)
Structural information for the whole Vpr molecule is
available through NMR [17,31-34]. These features enable
a detailed analysis of the polymorphisms in Vpr with
respect to CTL epitopes, structure-function of the protein,
and fitness of the virus for replication.
In this study, we have analyzed the predicted amino acid
sequences of Vpr from global HIV-1 isolates available
through the HIV database. Specifically, the extent of
genetic variation in Vpr in the form of polymorphisms at
the individual amino acid level was comprehensively ana-
lyzed. Several of the amino acid polymorphisms were
found to be part of the experimentally verified and pre-
dicted CTL epitopes. The location and nature of the vari-
ant amino acid were found to affect the CTL epitope
considerably. Hence, our results provide a glimpse into
the genetic footprints of immune evasion in Vpr.
Materials and methods
The goal of our studies is to assess the nature and extent of
polymorphisms at the level of individual residues in the
Vpr molecule. The sequences considered here comprise
Vpr sequences derived from all the major subtypes of HIV-
1. The details regarding the subtypes and the number of
sequences from each subtype are presented in Table 1 and
are taken from the HIV database http://www.hiv.lanl.gov
[35-38]. In addition, we have included Vpr sequences
derived from HIV-1 positive long term non-progressors
(McKeithen et al., unpublished data). It should be noted
that we have also included Vpr from SIV isolated from
chimpanzees, as this is likely the progenitor virus for HIV-
1. Vpr sequences from the database were accessed in Jan-
uary of 2007. The deletions in the Vpr molecule were
excluded from our analysis. The alignment of Vpr
sequences (which is available from the authors upon
request) was analyzed manually for variant amino acids at
the level of individual residue in Vpr from global and dis-
tinct subtypes of HIV-1.
Results
Characteristics of Vpr sequences selected for this study
The alignment of Vpr sequences has enabled us to analyze
the differences at the level of each residue from diverse
HIV-1 isolates. A total of 976 Vpr sequences have been
used for alignment. The polymorphisms, with respect to
the length, have been noted in Vpr by several investigators
[17,39]. As this may pose problem for our analysis, our
alignment does not take into account both deletions and
insertions. The Vpr alleles are from diverse subtypes and
include 67, 294, 185 and 44 Vpr sequences representing
subtype A, B, C, and D, respectively (Table 1). The O, AE,
AG, and cpx groups represent 39, 45, 39 and 28 Vpr
sequences, respectively. Since the Vpr sequences are
derived from different sources such as viral RNA, cloned
viral DNA and proviral DNA from tissues, we have not
made attempts to classify them in our analysis.
Amino acid polymorphisms in the predicted Vpr sequences
Recently, the structure of full length Vpr has been resolved
by NMR [40]. According to this study, Vpr consists of a
flexible N-terminal domain (amino acids 1–16), helical
domain I (HI) (residues 17–33), turn (residues 34–37),
helical domain II (HII) (residues 38–50), turn (residues
51–54), helical domain III (HIII) (residues 55–77), and a
flexible C-terminal domain (residues 78–96). Based on
this structure, the polymorphisms observed in Vpr are pre-
sented with respect to the individual domain.
N-terminus of Vpr (residues 1–16)
The results presented in Table 2 regarding the N-terminal
domain of Vpr show that all the residues excluding the
initiator methionine are susceptible for alterations. The
altered amino acids or polymorphisms at each residue are
indicated as variant amino acids or substitutions. For con-
venience, we have used Vpr from NL4-3 proviral DNA as
a reference sequence. The amino acid sequence of NL4-3
Vpr is similar to HIV-1 subtype B consensus Vpr except for
residues 28(S), 77(Q) and 83(I). Interestingly, the residue
9, which is G, has only one variant amino acid. In an ear-
lier study, it was noted that a change in residue 3 from Q
to R was not associated with cytopathic effect [41]. In our
analysis, variant amino acids H, L, M, and P were also
noted for Q. Studies involving synthetic peptides corre-
sponding to the N-terminus and also the full-length Vpr
Table 1: Vpr sequences used for the analysis of amino acid 
polymorphisms
Subtype Designation Number of Vpr Sequences
A6 7
B2 9 4
C1 8 5
D4 4
F1 6
F2 4
G8
H3
J2
K2
AE 45
AG 39
AB 3
Cpx 28
Others (includes DF, BC, CD, BG, 
01B, A1C, A1D, A1G, etc)
198
O3 9
N3
Cpz 4
Unclassified 3Virology Journal 2008, 5:99 http://www.virologyj.com/content/5/1/99
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molecule have shown that the Vpr sequence (residues
PHN) have the ability to form a γ-turn. The residue 15(H)
exhibits eleven, residue 16 (N) shows ten and residue 14
(P) shows four variant amino acids. While residue 2 has
two, residues 5 and 12 register three variant amino acids.
Residues 3, 4, 6, 7, 8, 10, 11, and 13 contain multiple var-
iant amino acids ranging from five to eleven. The N-termi-
nal domain contains a total of 79 variant amino acids. Of
these, non-conserved substitutions correspond to about
80% of the residues.
The impact of the majority of the polymorphisms on Vpr
functions is not clear. Substitution of alanine for proline
at residue 5 and 10 showed less or increased virion incor-
poration of Vpr, respectively [42]. Similarly, substitution
of alanine for residue 12 reduced the cell cycle arrest func-
tion of Vpr [43]. On the other hand, substitution at resi-
due 13 and 14 showed an increase in cell cycle arrest
[42,44]. Hence, the naturally occurring polymorphisms
are likely to affect the functions of Vpr.
Helical domain I (HI residues 17–33)
NMR studies of full length Vpr show that a region com-
prising the residues 17–33 adapt a helical structure. This
was also predicted by several algorithms. The polymor-
phisms observed for the residues 17–33 are presented in
Table 3. The characteristics of the residues with respect to
the variant amino acids are the following: residues 18, 23
and 26 show two substitutions; residue 20 has three sub-
stitutions; residues 25, and 29 show four substitutions;
Table 2: The polymorphisms in the N-Terminus of Vpr (residues 1–16)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of different clades Number of variants
1 M none none
2E D ,  K 2
3 Q H, L, M, P, R 5
4 A D, F, I, L, N, P, S, T, V 9
5P L ,  Q ,  S 3
6 E A, D, G, K, Q, S, V 7
7 D E, G, H, N, V 5
8 Q A, E, H, L, P, R 6
9G R 1
10 P A, L, N, S, T 5
11 Q A, E, S, P 4
12 R E, G, K 3
13 E A, D, I, G, Q, V 6
14 P H, L, Q, S 4
15 Y C, D, F, G, H, L, M, N, P, S, V 11
16 N A, D, E, H, I, P, Q, R, S, T 10
Table 3: The polymorphisms in Helical Domain I of Vpr (residues 17–33)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of different clades Number of variants
17 E A, D, G, Q, T, V 6
18 W G, R 2
19 T A, I, L, M, P, R, S, V 8
20 L I, M, V 3
21 E A, D, G, K, T 5
22 L F, I, M, P, T, V 6
23 L S, V 2
24 E D, G, K, Q, R 5
25 E A, D, G, K 4
26 L F, I 2
27 K I, M, N, Q, R 5
28 S A, D, E, G, H, I, K, N, Q, R, T, V 12
29 E D, G, Q, V 4
30 A D, P, S, T, V 5
31 V A, D, I, L, M, T 6
32 R G, K, Q, T, W, 5
33 H R 1Virology Journal 2008, 5:99 http://www.virologyj.com/content/5/1/99
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residues 21, 24, 27, 30 and 32 show five substitutions;
and residues 17, 22, and 31 register six substitutions and
residue 19 has eight substitutions. Interestingly, residue
28 exhibits the highest number of substitutions and resi-
due 33 has only one substitution. This domain exhibits a
total of 80 variant amino acids and 61 of them are of non-
conservative in nature.
Several laboratories including ours have reported on the
importance of residues in the helical domain I for Vpr
functions. Substitution of a proline residue for glutamic
acid (residue 17, 21, 24, 25, and 29) has a drastic effect on
the stability, subcellular localization, and virion incorpo-
ration of Vpr [44-49]. The variant amino acids noted in
this domain have the potential to destabilize and disrupt
the function of Vpr. Similarly, substitution of alanine for
leucine residue affected the stability and virion incorpora-
tion of Vpr [45,48,50-53]. Based on the studies reported,
varying amino acid arginine for histidine at residue 33
will affect the subcellular localization and virion incorpo-
ration of Vpr [54].
Interhelical domain I (residues 34–37)
This region is present between helical domains I and II
and comprises only four residues. It has been shown that
residues in this region have the ability to form a γ-turn.
The naturally occurring polymorphisms in this region are
presented in Table 4. Site-specific mutagenesis studies
have shown an important role for residues in subcellular
localization, cell cycle arrest, apoptosis and virion incor-
poration of Vpr [42,44,51,55,56]. Residues 34 and 35
show only three substitutions. On the other hand, residue
36 and 37 register 10 and 16 substitutions, respectively.
The variant amino acids reach a total of 31 and 21 of them
are of non-conservative in nature.
Helical domain II (residues 38–50)
Studies with peptide (1–50 amino acids) and full-length
Vpr have shown that residues 38–50 correspond to helical
domain II of Vpr. The naturally occurring polymorphisms
corresponding to the residues in this region are presented
in Table 5. The characteristics of the substitution are the
following: residues 39 and 47 exhibit a single substitu-
tion; residues 43, 46 and 50 record two substitutions; res-
idue 38 shows four substitutions; residues 42, 45 and 49
show five substitutions; and residues 40 and 44 have eight
substitutions. Nine and thirteen substitutions were noted
for residues 41 and 48, respectively. This domain contains
64 variant amino acids and non-conservative substitu-
tions correspond to 41 residues. Several laboratories have
carried out experiments addressing the role of residues in
this region by utilizing site-specific mutagenesis. The alter-
ation of hydrophobic residues severely affected the virion
incorporation and transcriptional activation of Vpr
[43,44,50,56].
Interhelical domain II (residues 51–54)
This region is located between helical domains II and III.
Of the four residues which are part of this domain, only
the residue G51 has been shown to reduce G2/M cell cycle
arrest through alanine substitution [44]. The naturally
occurring polymorphisms corresponding to the residues
in this region are presented in Table 6. The characteristics
of the substitutions are the following: residue 54 shows
two substitutions; residue 51 shows three substitutions;
residue 52 shows four substitutions and residue 53 shows
five substitutions. The variant amino acids reach a total of
fourteen and the majority of them are non-conservative
substitutions.
Helical domain III (residues 55–77)
The presence of helical domain III has been demonstrated
by NMR [40]. Several laboratories including ours have
shown the importance of this domain for the function of
Vpr. The naturally occurring polymorphisms noted for the
residues in this region are presented in Table 7. The char-
acteristics of the substitutions are the following: residues
56, 64, 65, 71 and 75 exhibit two substitutions; residues
69, 70, 72, 73 and 76 register three substitutions; residues
57, 66 and 68 show four substitutions; residues 60, 61
and 67 show six substitutions; residues 62 and 63 have
seven substitutions; residue 74 has eight substitutions;
residues 58, 59, and 77 exhibit ten substitutions; and res-
idue 55 shows eleven substitutions. While the variant
amino acids reach a total of 108, 65 of them are of non-
conservative nature. This region comprises LXXLL motif
which is important for subcellular localization and also
influences the virion incorporation of Vpr [44,57-62].
Additionally the LXXLL domain is also involved in Vpr-
GR interaction and its subsequent role in virus replication
[63,64].
Table 4: The polymorphisms in the Interhelical Domain 1 of Vpr (residues 34 – 37)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of different clades Number of variants
34 F L, V, Y 3
35 P H, L, S 3
36 R G, I, K, M, N, P, Q, S, T, W 10
37 I A, D, E, G, H, K, L, M, N, P, Q, R, S, T, V, Y 16Virology Journal 2008, 5:99 http://www.virologyj.com/content/5/1/99
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C-terminus of Vpr (residues 78–96)
The naturally occurring polymorphisms corresponding to
the residues in the C-terminus of Vpr are presented in
Table 8. The characteristics of the substitutions for the res-
idues in this region are the following: residue 80 has only
two substitutions; residues 78, 79, 82 and 92 have three
substitutions; residues 81 and 90 have four substitutions;
residues 91 and 96 have five substitutions. All of the other
residues have substitutions ranging from six to thirteen.
Of the 124 variant amino acids in this domain, 100 of
them are of non-conservative nature.
This domain contains multiple arginine and serine resi-
dues. It has been reported that the arginine residues are
important for the cell cycle arrest and subcellular localiza-
tion [65,66]. Vpr is known to undergo post-translational
modification and the serine residues located at 28, 79, 94,
and 96 positions of the protein serve as substrates for the
phosphorylation [67]. Vpr, devoid of phosphorylation
through site-specific mutagenesis, severely affects replica-
tion of HIV-1 in macrophages [68]. Residue 28 contains
equivalent proportion of amino acids N (44%) and S
(48%) and Vpr of SIV cpz contains N or T at this position.
On the other hand, serine residues at 79, 94, and 96 are
conserved in SIV cpz Vpr.
The naturally occurring polymorphisms for the whole Vpr
molecule reach a total of 498 substitutions. The non-con-
servative variant amino acids correspond to 72%. It is
important to note that all the residues in Vpr have the pro-
pensity to accept variant amino acids. The data presented
here also reveal that the variant amino acids noted with
respect to some residues are identical. These include resi-
dues 60(I), 61(I), 34(F), 71(H) and 72(F). We have car-
ried out a detailed analysis of the variant amino acids
noted in distinct subtypes (A, B, C, and D) of HIV-1. Such
an analysis could not be carried out for several groups
because of the limited information available regarding
Vpr alleles. The data generated for subtype B Vpr alleles
are presented in Tables 9, 10, 11, 12, 13, 14, 15. The anal-
ysis of subtype B involves a total of 275 Vpr alleles. As
expected, the extent of polymorphisms in subtype B is less
in comparison to the total polymorphisms noted with all
the Vpr alleles. Interestingly, there are several residues that
did not have any variant amino acids. These include resi-
dues 9, 18, 26, 34, 35, 38, 42, 46, 64, 66, and 79. On the
other hand, the residues without variant amino acids in
subtype C are different from that of subtype B except for
9, 26, and 64. In addition, the frequency of variant amino
acids at the level of each residue was also determined for
subtype B Vpr. The results indicate that the frequency of
variant amino acids is low in most cases (0.4–1.1%)
except for the residues 7, 19, 37, 41, 45, 55, 60, 63, 77, 80,
84, 85, 86, 89, and 93. Analysis involving a large number
of Vpr alleles also showed frequency patterns consistent
with the data presented in Tables 9, 10, 11, 12, 13, 14, 15.
With respect to the N-terminus domain (Table 9), the res-
idue 7 (D) has residue N substitution with a frequency of
Table 5: The polymorphisms in Helical Domain II of Vpr (residues 38 – 50)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of different clades Number of variants
38 W C, F, T, Y 4
39 L F 1
40 H I, L, M, N, Q, R, T, Y 8
41 N A, D, E, G, H, Q, R, S, W 9
42 L C, I, F, M, V 5
43 G E, R 2
44 Q E, H, L, K, N, R, T, V 8
45 H F, L, Q, W, Y 5
46 I D, V 2
47 Y H 1
48 E A, D, G, H, I, K, N, Q, R, S, T, V, Y 13
49 T H, N, M, S, Y 5
50 Y H, S 2
Table 6: The polymorphisms in Interhelical Domain II of Vpr (residues 51 – 54)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of different clades Number of variants
51 G E, K, R 3
52 D A, G, I, N 4
53 T A, L, N, P, S 5
54 W G, R 2Virology Journal 2008, 5:99 http://www.virologyj.com/content/5/1/99
Page 7 of 17
(page number not for citation purposes)
6.2%. Also, while the reference Vpr allele has Y at position
15, which is the predominant amino acid (85%), the var-
iant amino acid F occurs to a limited extent (6.9%). Simi-
lar scenario is also applicable to the residues 28, 77, and
83 (Tables 10 and 15). The residue R 80, which has been
implicated in cell cycle arrest function of Vpr, exhibits
substitution of A with a frequency of 5.1%.
Table 7: The polymorphisms in Helical Domain III of Vpr (residues 54–77)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of different clades Number of variants
55 A E, G, I, L, M, P, Q, R, S, T, V 11
56 G E, R 2
57 V A, L, M, W 4
58 E A, G, I, K, L, M, Q, R, T, V 10
59 A D, F, I, L, M, N, P, S, T, V 10
60 I F, L, M, T, V, Y 6
61 I A, L, M, T, V, Y 6
62 R I, K, L, Q, S, T, W 7
63 I F, L, M, S, T, V, Y 7
64 L F, V 2
65 Q H, R 2
66 Q H, K, L, R 4
67 L A, F, I, M, P, Q 6
68 L I, M, P, R 4
69 F L, S, V 3
70 I A, T, V 3
71 H L, Y 2
72 F S, Y, L 3
73 R G, S, T 3
74 I F, H, L, M, N, S, T, V 8
75 G K, R 2
76 C G, S, Y 3
77 R A, H, L, K, N, P, Q, S, T, W 10
Table 8: The polymorphisms in the Carboxy-Terminal Region of Vpr (residues 78–96)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of different clades Number of variants
78 H L, R, Y 3
79 S N, R, T 3
80 R A, K 2
81 I G, M, R, V 4
82 G A, D, S 3
83 V H, I, L, M, N, P, T, V 8
84 T A, F, G, I, L, M, N, P, Q, S, V, W, Y 13
85 R A, H, I, L, P, Q, T, V, Y 9
86 Q E, G, H, M, P, R, S, T, V, Y 10
87 R A, E, G, K, M, N, P, Q, S, T 10
88 R A, E, G, I, S, T 6
89 A D, E, G, I, L, N, P, R, S, T, V 11
90 R G, I, N, S 4
91 N D, H, I, K, S 5
92 G A, E, R 3
93 A D, F, G, L, M, N, P, S, T, V 10
94 S D, E, F, G, H, N, R, V 8
95 R A, D, G, I, K, P, S, T 8
96 S F, P, T, V, Y 5Virology Journal 2008, 5:99 http://www.virologyj.com/content/5/1/99
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Impact of amino acid polymorphisms on defined and 
predicted CTL epitopes in Vpr
It has been shown that a single amino acid change in the
epitope enables the virus to evade the T cell surveillance
[9,69]. Hence, it is of interest to analyze the polymor-
phisms in the context of both experimentally verified and
predicted CTL epitopes. As Vpr is a highly immunogenic
protein, several CTL epitopes have been already defined
[12]. CD8+ epitopes are contiguous and nine amino acids
long. The experimentally verified CTL epitopes in Vpr are
presented in Table 16 with their location in the protein.
We have presented the overall amino acid polymorphisms
for each of the epitope. The experimentally verified CTL
epitopes cluster in the region covering 1–70 residues of
Vpr. The total amino acid polymorphisms range from 36
to 107 for the individual epitopes. For example, the CTL
epitope comprising the residues REPHNEWTL contains
53 variant amino acids. Residues at position 1 to 9 of the
epitope show 3, 6, 4, 11, 10, 6, 2, 8, and 3 variant amino
acids, respectively.
In addition, we have also utilized bioinformatics
approach to assess the effect of polymorphisms on CTL
epitope http://Bimas.dcrt.nih.gov/molbio/hla-bind. The
predicted CTL epitopes with respect to several HLA class I
alleles are presented in Table 17. The impact of polymor-
phisms on the CTL epitope was assessed by determining
the estimate of half-time of disassociation of the molecule
Table 9: The frequency of variant amino acids in the N-Terminus of Vpr (Residues 1–16)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of subtype B*
1 M no change
2E D   (0.4)
3Q H   (0.4), R (1.8)
4A D   (0.7), T (0.4), V (1.1)
5P L   (0.4), S (0.4)
6E A   (1.1), D (0.4), K (1.1), Q (0.7)
7D N   (6.2), V (0.4)
8Q H   (1.1)
9 G no change
10 P L (0.4), S (0.7)
11 Q A (0.7), E (0.4), P (1.8), S (1.8)
12 R K (0.4)
13 E I (0.4), Q (1.1), V (0.7)
14 P Q (0.4), S (0.7)
15 Y C (0.4), D (0.4), F (6.9), H (5.0), N (0.7), S (0.4), V (0.4)
16 N A (0.4), H (1.1), I (0.4), Q (0.7), P (0.4), R (0.4), S (0.4), T (0.7)
*275 Vpr alleles were used for analysis.
The numbers in the parentheses represent the percent frequency of the variant amino acid in the Vpr alleles analyzed.
Table 10: The frequency of variant amino acids in Helical Domain I of Vpr (Residues 17–33)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of subtype B
17 E A (3.3), D (0.4), G (0.4), Q (2.2), V (0.4)
18 W no change
19 T A (12.7), R (0.4)
20 L I (4.4)
21 E G (0.4)
22 L F (0.4), I (1.1), P (0.4)
23 L V (0.4), S (0.4)
24 E G (0.4), K (0.4), Q (0.7), R (0.4)
25 E A (0.4), D (2.9), K (0.4)
26 L no change
27 K N (0.4)
28 S G (0.4), H (0.7), N (43.5), R (4.7), T (2.5)
29 E D (0.4), V (0.4)
30 A P (0.4)
31 V A (0.4), D (0.4), I (0.4), L (0.4), T (0.4)
32 R K (3.6), Q (0.4), W (0.4)
33 H R (3.6)Virology Journal 2008, 5:99 http://www.virologyj.com/content/5/1/99
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containing the epitope. For this purpose, we have consid-
ered 3, 1, 2, and 6 epitopes corresponding to HLA-A2, Cw-
4, HLA B-7 and HLA B-2705, respectively. The influence of
variant amino acids on the CTL epitope is presented in
Table 18, 19, 20 with respect to HLA-A2 molecule. The
epitopes considered for analysis correspond to residues
18–26, 38–46, and 66–74 of Vpr. While the reference pep-
tide of the epitope located at residues 18–26 (Table 18) of
Vpr shows the estimate of half time of disassociation value
of 1213.356, the variant amino acid at position 1–9 in the
epitope predicted a lower value. The substitution of vari-
ant amino acids at residue position 2 of the epitope
affected the half-time value considerably. Interestingly,
substitution of R lowered the value to 0.233. Similarly, the
substitution of F for L at position 9 of the epitope also
lowered the value to 4.233. The analysis of the epitope
corresponding to the residues 38–46 is shown in Table 19.
The variant amino acids at residue 39 and 41 drastically
lowered the value. The residue 46 showed contrasting val-
ues based on the nature of the variant amino acid present.
The impact of polymorphisms on the epitope correspond-
ing to the residues 66–74 is shown in Table 20. The results
show that both the location and nature of the amino acid
have an effect on the half-time disassociation of the mol-
ecule, which may lead to defective processing, presenta-
tion, and recognition of the epitope.
Discussion
Viral infections in individuals generally lead to a scenario
where the virus is confronted by the host immune system
involving both innate and adaptive immune responses.
Regarding the latter, cellular and humoral immune
responses have been shown to play a role in the control of
infections of viruses including HIV-1 [70,71]. It has been
suggested that an understanding of the correlates of pro-
tective immunity is an important requirement for the
development of vaccines against HIV-1. Several studies
have been published on this subject [71-73]. These studies
point out a role for CD8+ and CD4+ T cell responses and
neutralizing antibodies in the control of HIV-1 replica-
tion. For example, it has been reported that CD8+ cells
control HIV-1 in the acutely infected individuals [4-6].
The relevance of CD8+ T cells for the control of virus infec-
tion was also shown in the case of SIV infected rhesus
macaques [74,75]. Recently, the published data on CD8+
T cells in acute and chronic HIV-1 infection revealed that
CTL epitopes are present in all of the proteins encoded by
HIV-1. Virus replication, however, is not completely con-
tained due to the emergence of CTL escape variant viruses.
Based on this, it is suggested that vaccine efforts to control
HIV-1 should take into account the high genetic variabil-
ity noted among HIV-1.
The continued emergence of genetic variants is a charac-
teristic feature of RNA viruses. RNA dependent RNA
polymerase and reverse transcriptase are error-prone
Table 11: The frequency of variant amino acids in the Interhelical Domain 1 of Vpr (Residues 34–37)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of subtype B
34 F no change
35 P no change
36 R G (1.1), W (1.8), S (1.5)
37 I A (1.5), E (3.6), G (1.1), K (0.4), L (1.8), M (2.5), N (0.4), P (16), R (0.4), S (0.7), T (7.6), V (19.3)
Table 12: The frequency of variant amino acids in Helical Domain II of Vpr (Residues 38–50)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of subtype B
38 W no change
39 L F (0.4), I (0.4)
40 H L (2.2), N (0.4), Q (1.5), R (0.4), T (0.4), Y (0.4)
41 N A (0.7), D (0.7), E (0.4), G (52.0), S (30.5)
42 L no change
43 G E (0.4), R (0.4)
44 Q R (0.4)
45 H F (0.7), L (1.1), Q (0.4), Y (24.4)
46 I no change
47 Y H (0.4)
48 E A (0.4), D (2.5), G (1.1), K (0.4), Q (0.4), V (0.4)
49 T N (0.7)
50 Y S (0.4)Virology Journal 2008, 5:99 http://www.virologyj.com/content/5/1/99
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enzymes and have been implicated as a cause for the gen-
eration of variants [76,77]. The mutational changes in the
protease and reverse transcriptase, depending on their
location, may impact on their binding inhibitors targeting
these enzymes. The viruses containing alterations may
then be able to evade the inhibitory activities of the agents
and are designated as drug-resistant variants. Similarly,
the mutations in Env, Tat, and possibly other proteins can
also evade the neutralizing antibody, CTL and T-helper
cell responses [12,71]. The emergence of escape variants
eventually repopulates the body in the face of immune
responses against the virus. It has been suggested that
immune escape may be a key step in the evolution of HIV-
1 [30,78-80].
In an effort to understand the overall polymorphisms in a
HIV-1 gene product, we undertook a comprehensive anal-
ysis of the predicted amino acid sequences of Vpr from
diverse HIV-1 subtypes. Considering the genetic variation
noted in diverse HIV-1 [39], our hypothesis is that the dif-
ferences in Vpr and other viral proteins may enable the
viruses to escape the host immunological pressures. To
address this issue, we have initially compiled the poly-
morphisms in Vpr at the level of individual amino acid.
Vpr contains only 96 amino acids. Hence, the small size
of the protein is an advantage for a comprehensive analy-
sis. For this purpose, we have turned to the Vpr sequences
which are available in the HIV database and also
sequences from specific groups such as HIV-1 positive
long-term non-progressors. A total of 976 predicted Vpr
amino acid sequences were used for our studies. The anal-
ysis revealed several characteristic features with respect to
the individual amino acids in the Vpr. Of the 96 amino
acids, all the amino acids except the initiator methionine
have the propensity to change. This indicates that Vpr
molecule is highly flexible in nature. The frequency of the
variant amino acids, calculated for subtype B Vpr at the
level of individual residue, revealed that substitution is
very low for most of the residues. This suggests that many
of the substitutions in Vpr may compromise the function
and possibly the fitness of the virus. Interestingly, there
are several amino acids that can accommodate ten or
Table 13: The frequency of variant amino acids in Interhelical Domain II of Vpr (Residues 51 – 54)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of subtype B
51 G E (0.7), K (0.4)
52 D N (0.7), I (0.4)
53 T A (0.4), L (0.4)
54 W R (0.4), G (0.4)
Table 14: The frequency of variant amino acids in Helical Domain III of Vpr (Residues 55–77)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of subtype B
55 A E (2.2), P (1.1), Q (0.4), T (19.6), V (1.8)
56 G R (0.4), E (0.7)
57 V W (0.4)
58 E G (1.1), I (0.4), K (1.1), Q (0.7), V (0.4)
59 A L (0.4), P (0.4), S (0.4), V (0.4)
60 I L (16.4)
61 I L (0.4), M (1.1), T (3.3), V (1.5)
62 R K (0.7), L (0.4), S (0.4)
63 I M (5.8), S (1.8), T (11.3), V (1.8)
64 L no change
65 Q H (0.4)
66 Q no change
67 L M (1.5), P(0.7)
68 L M (1.5)
69 F L (1.8)
70 I T (2.9), V (1.1)
71 H L (0.4), Y (0.4)
72 F S (1.5), Y (0.4)
73 R T (0.7)
74 I L (0.4), M (0.4), V (0.4)
75 G R (1.1)
76 C G (1.1)
77 R H (5.5), Q (42.5)Virology Journal 2008, 5:99 http://www.virologyj.com/content/5/1/99
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more alterations. We designate such amino acids as hot
spots in Vpr which include residues 15, 16, 28, 36, 37, 48,
55, 58, 77, 84, 86 and 89. The underlying basis for the
extensive genetic changes in specific regions of Vpr is not
clear. It is likely that the error-prone reverse transcriptase,
the secondary structure of RNA and other factors, either
alone and/or in combination may play a role in the gen-
eration of genetic variants. In this regard, Yusim et al. [28]
have noted that Integrase (IN) exhibits the least variability
and Vpu exhibits the highest variability. Boutwell and
Essex [27] also showed that the proportion of polymor-
phic amino acids ranged from a low of 55% (RT, IN) to a
high of 94% (Vpu). In our analysis, Vpr variability is high
which may likely be due to the inclusion of diverse iso-
lates including the HIV-1 progenitor virus SIVcpz.
Vpr is known as a highly immunogenic protein. The pres-
ence of CTL epitopes verified through experimental
approaches has been reported by several groups [12].
These include the region encompassing residues 9–70 of
Table 15: The frequency of variant amino acids in the Carboxy-Terminal Region of Vpr (Residues 78–96)
Residue Residues in NL4-3 Vpr Variant residue(s) noted in viruses of subtype B
78 H L (0.7)
79 S no change
80 R A (5.1)
81 I G (0.4), M (0.7), V (0.4)
82 G D (0.7), S (0.7)
83 V I (86.9), L (0.4), T (0.7)
84 T A (0.4), F (0.4), G (0.7), I (30.9), L (2.5), M (0.4), N (0.7), S (0.4), V (0.4)
85 R H (0.4), I (0.4), L (2.5), P (15.6), Q (28.4), T (0.4), Y (1.1)
86 Q M (0.4), P (1.1), R (21.1), S (1.5), V (1.1)
87 R A (0.4), G (1.5), K (0.4), M (0.4), N (0.4), S (3.3), T (3.6)
88 R A (2.2), G (1.5), I (0.4), S (0.4), T (0.7)
89 A E (0.7), G (0.4), P (0.7), R (2.2), S (2.2), T (10.2), V (0.4)
90 R G (0.4), N (0.4), S (0.4)
91 N D (1.5), H (0.4), I (0.4), K (0.4)
92 G A (0.4), E (0.4), R (0.7)
93 A D (0.4), L (0.4), P (0.7), S (6.5), T (2.2), V (0.4)
94 S F (0.4), G (2.5), N (1.1), R (3.3), V (0.4)
95 R A (0.4), D (0.4), I (0.4), K (0.4), T (1.1), S (0.4)
96 S P (4.0)
Table 16: The extent of amino acid polymorphisms in experimentally defined CTL epitopes
Location of the epitope in Vpr Amino acid sequence Total number of variant amino acids in the CTL 
epitope
Reference
1 – 18 MEQAPENQGLQREPYNEW 87 [86]
9 – 26 GPQREPYNEWTLELLEEL 87 [87]
12 – 20 REPHNEWTL 53 [28,88,89]
19 – 28 TLEILEELKN 51 [86]
25 – 40 ELKNEAVRHFPRIWLH 87 [90]
29 – 37 EAVRHFPRI 52 [91-94]
30 – 38 AVRHFPRIW 52 [28,88,95]
31 – 50 VRHFPRWLHSLGQYIYETY 107 [96]
31 – 39 VRHFPRIWL 48 [97]
34 – 42 FPRIWLHGL 58 [28,87,89,97-103]
41 – 49 SLGQHIYET 49 [99]
41 – 57 GLGQYIYETYGDTWTGV 82 [87]
46 – 54 IYETYGDTW 36 [104]
48 – 57 ETYGDTWTGV 50 [87,97]
52 – 62 DTWAGVEAIIR 66 [97]
53 – 63 TWAVEAIIRI 69 [92]
55 – 70 AGVEAIIRILQQLLFI 86 [28]
59 – 67 AIIRILQQL 49 [10,28,89,96,98,105,106]
62 – 70 RILQQLLFI 38 [89,98,106]Virology Journal 2008, 5:99 http://www.virologyj.com/content/5/1/99
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Vpr. Of the 96 residues, 62 (65%) have been shown to be
associated with experimentally defined CTL epitopes. The
data presented in Table 16 show that there are polymor-
phisms with respect to the experimentally verified CTL
epitopes. The presence of variant amino acids at distinct
locations within the epitope is likely to impact the CTL
epitope. Further, we have also evaluated the effect of Vpr
polymorphisms on CTL epitopes using the bioinformatics
approach by calculating the estimate of half time of disas-
sociation of the molecule containing the epitope. Such an
analysis predicted several CTL epitopes all over Vpr
including the C-terminus with respect to specific HLA
class 1 molecules. The detailed analysis was carried out for
different HLA alleles (HLA-A2, Cw-4, HLA-B7 and HLA-
B2705) involving a total of 12 epitopes. The polymor-
phisms have also been analyzed for three predicted
epitopes corresponding to residues 18–26, 38–46, and
66–74. The substitution of the variant amino acids for the
residues comprising the epitope resulted in a drastic
reduction in the value corresponding to the half time of
the disassociation of the molecule containing the epitope.
It should, however be noted that additional in vitro bind-
ing studies are necessary to confirm the predicted values.
Based on the data presented here, the amino acid poly-
morphisms noted in Vpr have the potential to contribute
to the escape of the virus along with the epitopes present
in other HIV-1 proteins [30]. It is also likely that the infor-
mation regarding the polymorphisms at the CTL epitope
will provide an opportunity to create an epitope-based
vaccine that will exert control over viral isolates from dif-
ferent parts of the world. It is important to mention that
the extensive HLA-associated amino acid polymorphisms
noted here may also impact on the structure/function of
Vpr and fitness of the virus [10,81-85]. The biological
sources used for generating the sequence information of
vpr include tissues from infected individuals, plasma viral
RNA, and cloned viral DNA. For this reason, the Vpr
sequences considered here for the analysis may be derived
from both infectious and non-infectious viral genomes.
Hence, there is a possibility that the amino acid polymor-
phisms noted here may or may not have a chance to be
acted upon by CTL and T-helper cell pressures. It is known
that amino acids in the proximal region of the epitope can
also influence their immunogenic potential. The amino
acid polymorphisms noted in the putative CTL epitopes
can have an effect at a single and/or multiple levels in the
generation of immune response: i) The mutations may
eliminate the binding of the peptide to the appropriate
HLA molecule, which will be presented on the cell surface.
ii) Mutations may also disrupt the interaction with the T-
cell receptors. iii) Mutations may disrupt the intracellular
processing of the peptides. This results in the escape of the
cells expressing the viral proteins from the surveillance of
CD8+ T cells. The variant amino acids present in the prox-
imal or far away from the epitope could influence through
interference with the processing of the peptide from the
protein. With regard to the latter, the variant amino acids
may be either independent or compensatory in relation to
changes in specific residues of Vpr. In addition, variant
amino acids, which are part of overlapping epitopes pre-
sented by different HLA molecule, can also exert an influ-
ence on the epitope [30].
HIV variability is an important factor that should be taken
into account in the efforts directed towards the develop-
Table 17: The predicted HLA Class 1 CTL epitopes in HIV-1 Vpr
Location of the predicted epitope Amino acid sequence HLA allele
7 – 15 DQGPQREPY B62
8 – 16 QGPQREPYN Dd
11 – 19 QREPYNEWM B_2705
14 – 22 PYNEWMLDL A24, Kd
18 – 26 WMLDLLEDL A_0201, A_0205, B_2705, B_3901, Db_revised, Kd
26 – 34 LKHEAVRHF Cattle_A20
31 – 39 VRHFPRPWL B_2705
34 – 42 FPRPWLHEL B7, Cw_0401
38 – 46 WLHELGQQI A_0201
39 – 47 LHELGQQIY B_3801
49 – 57 TYGDTWEGV Kd
60 – 68 IVRTLQQLL B7
61 – 69 VRTLQQLLF B_2702, B_2705
64 – 72 LQQLLFVHF B62, B_2705, B_3902
65 – 73 QQLLFVHFR A_3101, B_2705, Cattle_A20
66 – 74 QLLFVHFRI A_0201
72 – 80 FRIGCQHSR B_2705, Cattle_A20
79 – 87 SRIGIIRGR B_2705, Cattle_A20
87 – 95 RRGRNGSGR B_2705, Cattle_A20Virology Journal 2008, 5:99 http://www.virologyj.com/content/5/1/99
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ment of vaccines against HIV-1. In order for the vaccines
to be effective against diverse HIV-1, strategies that are
being considered include consensus sequence approaches
and polyvalent vaccines in the form of a mixture of genes/
proteins from different subtypes of HIV-1. Despite the
extensive variability reported for HIV-1, the nature and
extent of variation has not been systematically investi-
gated. Such an analysis is difficult to carry out for HIV-1
Gag, Pol or Env protein due to its size. It is for this reason
that we have selected Vpr, a small protein. The results pre-
sented for Vpr here are interesting and novel as they
describe genetic variation involving global HIV-1. Surpris-
ingly, the frequency of the variant amino acids for most of
the residues is low. This suggests that majority of the resi-
Table 18: Effect of variant amino acids on CTL epitope 
corresponding to residues 18–26 of Vpr
Amino Acid Sequence of Predicted Epitope Scoreβ
Prototype sequence (start position 18)α
WMLDLLEDL 1,213.356
Natural variations observed at this epitope
GMLDLLEDL 263.773
RMLDLLEDL 263.773
WALDLLEDL 23.334
WILDLLEDL 231.004
WLLDLLEDL 1,680.031
WPLDLLEDL 10.967
WRLDLLEDL 0.233
WSLDLLEDL 10.967
WVLDLLEDL 147.003
WTLDLLEDL 23.334
WMIDLLEDL 327.934
WMMDLLEDL 1,213.356
WMVDLLEDL 327.934
WMLALLEDL 295.940
WMLELLEDL 1,213.356
WMLGLLEDL 295.940
WMLKLLEDL 295.940
WMLTLLEDL 295.940
WMLDLSEDL 527.546
WMLDLVEDL 1,213.356
WMLDLLDDL 1,213.356
WMLDLLGDL 321.911
WMLDLLKDL 2,476.237
WMLDLLQDL 2,476.237
WMLDLLRDL 495.247
WMLDLLEDF 4.233
WMLDLLEDI 592.569
α Accession No.: A1.TZ.01.A341_AY253314
β Estimate of Half Time of Disassociation of a Molecule Containing 
This Epitope
Table 19: Effect of variant amino acids on CTL Epitope 
corresponding to residues 38–46 of Vpr
Amino Acid Sequence of Predicted Epitope Scoreβ
Prototype sequence (start position 38)α
WLHELGQQI 196.763
Natural variations observed at this epitope
CLHELGQQI 42.774
FLHELGQQI 196.763
TLHELGQQI 42.774
YLHELGQQI 196.763
WFHELGQQI 0.137
WLIELGQQI 196.763
WLLELGQQI 728.022
WLMELGQQI 728.022
WLNELGQQI 196.763
WLQELGQQI 196.763
WLRELGQQI 14.954
WLTELGQQI 196.763
WLYELGQQI 629.64
WLHALGQQI 47.991
WLHDLGQQI 196.763
WLHGLGQQI 47.991
WLHHLGQQI 47.991
WLHNLGQQI 47.991
WLHQLGQQI 47.991
WLHRLGQQI 47.991
WLHSLGQQI 47.991
WLHWLGQQI 47.991
WLHECGQQI 196.763
WLHEFGQQI 747.698
WLHEIGQQI 196.763
WLHEMGQQI 196.763
WLHEVGQQI 196.763
WLHELGEQI 96.414
WLHELGHQI 196.763
WLHELGKQI 196.763
WLHELGLQI 196.763
WLHELGNQI 196.763
WLHELGRQI 39.353
WLHELGTQI 196.763
WLHELGVQI 196.763
WLHELGQFI 1082.194
WLHELGQHI 196.763
WLHELGQLI 196.763
WLHELGQWI 1082.194
WLHELGQYI 1082.194
WLHELGQQD 0.281
WLHELGQQV 1311.751
α Accession No.: A1.TZ.01.A341_AY253314
β Estimate of Half Time of Disassociation of a Molecule Containing 
This EpitopeVirology Journal 2008, 5:99 http://www.virologyj.com/content/5/1/99
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dues cluster around a sequence shared by HIV-1 isolates of
different subtypes. It is likely that the influence of the res-
idues on the fitness of the virus counters the variability,
thus limiting the genetic variation. The information on
Vpr polymorphisms will be of value for the development
of vaccines based on the auxiliary genes of HIV-1.
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